NASDAQ · TNGX

Tango Therapeutics, Inc.

$26.63 -$0.82 (-2.99%) 1D After hours

Key Metrics

$4.47B
Market cap
P/E · TTM
$56.99M
Revenue · TTM
−$107.23M
Net income
EPS · TTM $-0.97
Dividend yield
Free cash flow −$142.54M
Beta · 1Y 1.18
EBITDA · TTM −$105.14M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 8
    The stock moved +53.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 8
  • May 27
    From its Apr 21 high, the share price fell 29%.

    Peak close $27.77 on Apr 21; trough close $19.65 on May 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -29%
  • Mar 5
    The stock moved +36.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.47B
Enterprise value
Shares outstanding162.8M
52-wk range$5.77 – $34.39
Avg volume · 20D1.3M
Net cash
Book value / share$3.55
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Tango Therapeutics, Inc.
IPO dateAug 11, 2021
Employees137

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S78.42
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -188.2%
Net -188.2%
FCF -250.1%
ROE / ROIC -36.3% · -919.1%

Financial Health

Current ratio27.38
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$378.00M

Cash Flow · TTM

Operating CF −$141.55M
Capex −$995.00K
Free cash flow −$142.54M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

58.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings